News

National Cancer Institute selects Apexian Pharmaceuticals to participate in the Small Business Innovation Research (SBIR) Initiative program

Indianapolis, IN – September 27, 2017 –Apexian Pharmaceuticals is pleased to announce that the National Cancer Institute (NCI) has selected the company to participate in its highly competitive Small Business Innovation Research (SBIR) Investor Initiatives program, that encourages domestic small businesses to engage in Research and Development (R&D) that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore...

Apexian Pharmaceuticals Announces FDA Agreement For Inclusion of Chemotherapy Induced Peripheral Neuropathy (CIPN) Indication Under Currently Approved IND

Indianapolis, IN – July 13, 2017 – Apexian Pharmaceuticals, a clinical stage biotechnology company developing novel compounds to treat cancer, today announced that it has received FDA agreement that the currently approved IND can be used to examine Chemotherapy Induced Peripheral Neuropathy (CIPN) as an indication in addition to its anti-tumor effects. APX3330, the lead molecule for Apexian has a dual biological role through the...